NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitive Revision Award (P01 and P50)

archived

Purpose. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) solicits Accelerating Research Translation (ART) applications in musculoskeletal and skin tissue engineering and regenerative medicine (TE/RM). The ART awards intend to offer revision support (formerly referred to as a competing supplement) to active NIAMS R01, P01 and P50 (parent) grants for conducting large animal pre-clinical studies with the potential to immediately lead to human trials in musculoskeletal and skin TE/RM. These studies will 1) provide data required for Phase I/II human clinical trials in musculoskeletal and skin TE/RM, 2) demonstrate efficacy of a TE/RM therapy in musculoskeletal and skin TE/RM, or 3) develop pre-clinical large animal models that will have the potential to immediately lead TE/RM research into Phase I/II clinical trials. Early stage translational studies using small animals such as rodent and rabbit are not responsive to this FOA. Mechanism of Support. This FOA will utilize the NIH revision to P01 and P50 grant mechanism and runs in parallel with a FOA (RFA-AR-11-004) of identical scientific scope that solicits applications under the NIAMS R01 mechanism. Funds Available and Anticipated Number of Awards. The NIAMS plans to commit $1M in total cost in FY 2011 to make 1 to 3 ART awards for both RFA-AR-11-004 and RFA-AR-11-005. Awards issued under this FOA are contingent upon the availability of funds and the submission of meritorious applications.

High